戻る Agenda
Paying for Value in Biopharmaceuticals: Trends in the United States
Session Chair(s)
Sudip Parikh, PHD
Chief Executive Officer and Executive Publisher, Science Journals
American Association for the Advancement of Science (AAAS), United States
Recent political and media attention has focused on the cost of medicines, with U.S. politicians and some consumer organizations demanding lower prices, as well as more transparency around pricing that all too frequently seems opaque. At the same time, U.S. health care is transitioning to focus more on paying for the value of care provided, rather than on the volume of goods and services, including for drugs. This DIAmond session will provide context on how drug pricing, reimbursement, and purchasing decisions are evolving in the US. Topics to be explored include how U.S. biopharmaceutical prices are determined in contrast to other countries; the roles of different players, such as pharmacy benefit managers, in the system; and how payers and manufacturers are embracing new value-based arrangements to make more efficient and effective use of the dollars spent on biopharmaceuticals.
Learning Objective : Discuss the decision making process for drug pricing, reimbursement, and access to medicines; Define value and its impact on health care spending
Speaker(s)
Panelist
Sloane Salzburg, MS
Prescriptions For A Healthy America, United States
Executive Director
Panelist
Shawn Davis
Express Scripts, United States
Senior Director, Formulary Solutions
Panelist
Joel Beetsch, PHD
Celgene Corporation, United States
Vice President, Global Patient Advocacy
Panelist
Phillip J. Lerner, MD, MPH
Aetna, Inc., United States
Vice President and National Medical Director